ISIS ApoC-III Rx

is ApoC-III targeted antisense oligonucleotide (ISIS ApoC-III Rx) · Ionis Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ISIS ApoC-III Rx, covering 2022-01-27 to 2022-01-27. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia [Phase 2]